Abstract
Meropenem is a logical choice for monotherapy Clinical researchers compared the efficacy and safety of meropenem and imipenem/cilastatin in 232 hospitalised adult patients with proven abdominal infections. Patients enrolled in the multicenter study were randomised to receive IV meropenem or imipenem/cilastatin every 8 hours for 5-10 days. Clinical cure or improvement was seen in > 97% of the patients in both treatment groups. Bacteriological eradication was confirmed in 84% and 81 % of the meropenem and imipenem groups. respectively, a nonsignificant difference. Thus. meropenem alone proved to he as effective as imipenem combined with cilastatin in the treatment of intra-abdominal infections, and was well tolerated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
